CN101415417A - (2r,z)-2-氨基-2-环己基-n-(5-(1-甲基-1h-吡唑-4-基)-1-氧代-2,6-二氢-1h-[1,2]二氮杂卓并[4,5,6-cd]吲哚-8-基)乙酰胺的组合疗法 - Google Patents

(2r,z)-2-氨基-2-环己基-n-(5-(1-甲基-1h-吡唑-4-基)-1-氧代-2,6-二氢-1h-[1,2]二氮杂卓并[4,5,6-cd]吲哚-8-基)乙酰胺的组合疗法 Download PDF

Info

Publication number
CN101415417A
CN101415417A CNA2007800121818A CN200780012181A CN101415417A CN 101415417 A CN101415417 A CN 101415417A CN A2007800121818 A CNA2007800121818 A CN A2007800121818A CN 200780012181 A CN200780012181 A CN 200780012181A CN 101415417 A CN101415417 A CN 101415417A
Authority
CN
China
Prior art keywords
oxo
cyclohexyl
dihydro
amino
acetamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800121818A
Other languages
English (en)
Chinese (zh)
Inventor
肯纳·里恩·安德瑞斯
亚历山卓·比拉西那
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of CN101415417A publication Critical patent/CN101415417A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2007800121818A 2006-04-04 2007-03-26 (2r,z)-2-氨基-2-环己基-n-(5-(1-甲基-1h-吡唑-4-基)-1-氧代-2,6-二氢-1h-[1,2]二氮杂卓并[4,5,6-cd]吲哚-8-基)乙酰胺的组合疗法 Pending CN101415417A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US78927606P 2006-04-04 2006-04-04
US60/789,276 2006-04-04

Publications (1)

Publication Number Publication Date
CN101415417A true CN101415417A (zh) 2009-04-22

Family

ID=38421777

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800121818A Pending CN101415417A (zh) 2006-04-04 2007-03-26 (2r,z)-2-氨基-2-环己基-n-(5-(1-甲基-1h-吡唑-4-基)-1-氧代-2,6-二氢-1h-[1,2]二氮杂卓并[4,5,6-cd]吲哚-8-基)乙酰胺的组合疗法

Country Status (14)

Country Link
US (1) US20090312280A1 (enExample)
EP (1) EP2007375A1 (enExample)
JP (1) JP2007277240A (enExample)
KR (1) KR20080100838A (enExample)
CN (1) CN101415417A (enExample)
AR (1) AR060284A1 (enExample)
AU (1) AU2007232279B2 (enExample)
BR (1) BRPI0709731A2 (enExample)
CA (1) CA2648371A1 (enExample)
IL (1) IL194340A0 (enExample)
MX (1) MX2008012791A (enExample)
RU (1) RU2409361C2 (enExample)
TW (1) TW200806301A (enExample)
WO (1) WO2007113671A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2009113436A1 (ja) * 2008-03-14 2011-07-21 国立大学法人 千葉大学 Ｆｇｆｒ３遺伝子阻害剤の放射線照射併用による放射線の抗癌作用増強法および副作用軽減法
RU2482855C2 (ru) * 2008-03-27 2013-05-27 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевое средство, включающее производное цитидина и карбоплатин
JP5805071B2 (ja) * 2009-04-11 2015-11-04 アレイ バイオファーマ、インコーポレイテッド Ｄｎａ損傷因子増強のためのチェックポイントキナーゼ１阻害剤
US8481557B2 (en) 2009-04-11 2013-07-09 Array Biopharma Inc. Method of treatment using checkpoint kinase 1 inhibitors
CA2817968C (en) 2010-11-16 2019-03-12 Array Biopharma Inc. Combination of checkpoint kinase 1 inhibitors and wee 1 kinase inhibitors
RS56616B1 (sr) 2011-12-31 2018-02-28 Beigene Ltd Kondenzovani tetra ili penta-ciklični dihidrodiazepinokarbazoloni kao parp inhibitori
NZ626937A (en) 2011-12-31 2016-09-30 Beigene Ltd Fused tetra or penta-cyclic pyridophthalazinones as parp inhibitors
CA2938626A1 (en) 2013-07-26 2015-01-29 John Rothman Compositions to improve the therapeutic benefit of bisantrene
EP3461480A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dna damage response cell cycle checkpoint inhibitors and belinostat for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9704545D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
DK1585749T3 (da) * 2003-01-09 2008-09-22 Pfizer Diazepinoindol-derivater som kinaseinhibitorer

Also Published As

Publication number Publication date
AR060284A1 (es) 2008-06-04
BRPI0709731A2 (pt) 2011-07-26
US20090312280A1 (en) 2009-12-17
MX2008012791A (es) 2008-10-15
CA2648371A1 (en) 2007-10-11
AU2007232279A1 (en) 2007-10-11
TW200806301A (en) 2008-02-01
AU2007232279B2 (en) 2010-05-06
JP2007277240A (ja) 2007-10-25
WO2007113671A1 (en) 2007-10-11
EP2007375A1 (en) 2008-12-31
IL194340A0 (en) 2009-08-03
KR20080100838A (ko) 2008-11-19
RU2409361C2 (ru) 2011-01-20
RU2008139406A (ru) 2010-04-10

Similar Documents

Publication Publication Date Title
AU2007232279B2 (en) Combination therapy of (2R)-2-amino-2-cyclohexyl-N-(2-(1-methyl-1H-pyrazol-4-yl)-6- oxo-5,6-dihydro-1H-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
MX2007003314A (es) Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas.
US20050272755A1 (en) Method for treating abnormal cell growth
CN101573358A (zh) 吡啶并(2,3-d)嘧啶酮化合物及其作为pi3抑制剂的用途
CN110678169A (zh) Chk1-抑制剂与weel-抑制剂的组合
CN117062799A (zh) 新的方法
CA3092003A1 (en) Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor
CN110267681A (zh) 使用对肿瘤相关抗原特异性的治疗性单克隆抗体和免疫佐剂治疗癌症
CN101384264B (zh) 含有聚（adp-核糖）聚合酶抑制剂的治疗组合物
HK1131034A (en) Combination therapy of (2r,z)-2-amino-2-cyclohexyl-n-(5-(1-methyl-1h-pyrazol-4-yl)-1-oxo-2,6-dihydro-1h-[1,2]diazepino[4,5,6-cd]indol-8-yl)acetamide
US20110236506A1 (en) Pharmaceutical association containing lipoic acid and hydroxycitric acid as active ingredients
US10494412B2 (en) Peptides
AU2011253816A1 (en) Therapeutic combinations comprising poly(ADP-ribose) polymerases inhibitor
HK1127956A (en) Therapeutic combinations comprising poly(adp-ribose) polymerases inhibitor
CN120349384A (zh) 一种能引起肿瘤细胞免疫原性死亡的多肽及其制备方法、给药系统和应用
WO2010081778A1 (en) Blockers of parp for the prevention and treatment of helicobacter pylori induced gastric cancer
CN102448454A (zh) 包含plk1抑制剂和抗肿瘤剂的治疗性组合

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1131034

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20090422

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1131034

Country of ref document: HK